Literature DB >> 17985249

The immune response to respiratory syncytial virus infection: friend or foe?

Robert C Welliver1.   

Abstract

The immune response to respiratory syncytial virus (RSV) infection has fascinated and frustrated investigators for decades. After adverse responses to early attempts at vaccination, it became popularly held that disease following infection was related to overly aggressive immune responses. However, recent data illustrate that severe forms of disease are related to inadequate, rather than hyperresponsive, adaptive immune reactions. Thus, recovery from primary (and perhaps later) RSV infection is dependent on the quality of innate immune responses. These findings should have enormous significance to the development of vaccines and antiviral compounds.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17985249     DOI: 10.1007/s12016-007-8033-2

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  99 in total

1.  Association between surfactant protein A gene locus and severe respiratory syncytial virus infection in infants.

Authors:  Johan Löfgren; Mika Rämet; Marjo Renko; Riitta Marttila; Mikko Hallman
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

2.  Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin.

Authors:  V Bitko; A Velazquez; L Yang; Y C Yang; S Barik
Journal:  Virology       Date:  1997-06-09       Impact factor: 3.616

3.  Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis.

Authors:  R P Garofalo; J Patti; K A Hintz; V Hill; P L Ogra; R C Welliver
Journal:  J Infect Dis       Date:  2001-07-13       Impact factor: 5.226

4.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

5.  Surfactant protein-A enhances respiratory syncytial virus clearance in vivo.

Authors:  A M LeVine; J Gwozdz; J Stark; M Bruno; J Whitsett; T Korfhagen
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

6.  Increase in CD23+ B cells in infants with bronchiolitis is accompanied by appearance of IgE and IgG4 antibodies specific for respiratory syncytial virus.

Authors:  S Rabatić; A Gagro; R Lokar-Kolbas; V Krsulović-Hresić; Z Vrtar; T Popow-Kraupp; V Drazenović; G Mlinarić-Galinović
Journal:  J Infect Dis       Date:  1997-01       Impact factor: 5.226

7.  Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years.

Authors:  R T Stein; D Sherrill; W J Morgan; C J Holberg; M Halonen; L M Taussig; A L Wright; F D Martinez
Journal:  Lancet       Date:  1999-08-14       Impact factor: 79.321

8.  Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus.

Authors:  A H Cherrie; K Anderson; G W Wertz; P J Openshaw
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Airway eicosanoids in acute severe respiratory syncytial virus bronchiolitis.

Authors:  Yves Sznajer; Jay Y Westcott; Sally E Wenzel; Bruce Mazer; Marisa Tucci; Baruch Joseph Toledano
Journal:  J Pediatr       Date:  2004-07       Impact factor: 4.406

Review 10.  Respiratory syncytial virus and pulmonary surfactant.

Authors:  Matthias Griese
Journal:  Viral Immunol       Date:  2002       Impact factor: 2.257

View more
  18 in total

1.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

2.  Cutting edge issues in autoimmunity.

Authors:  Yaniv Sherer; Torsten Matthias; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

Review 3.  The airway epithelium: soldier in the fight against respiratory viruses.

Authors:  Marjolaine Vareille; Elisabeth Kieninger; Michael R Edwards; Nicolas Regamey
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Human metapneumovirus inhibits the IL-6-induced JAK/STAT3 signalling cascade in airway epithelium.

Authors:  Dana N Mitzel; Richard J Jaramillo; Heather Stout-Delgado; Albert P Senft; Kevin S Harrod
Journal:  J Gen Virol       Date:  2013-10-10       Impact factor: 3.891

Review 5.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

6.  Immunobiotic Lactobacillus administered post-exposure averts the lethal sequelae of respiratory virus infection.

Authors:  Caroline M Percopo; Tyler A Rice; Todd A Brenner; Kimberly D Dyer; Janice L Luo; Kishore Kanakabandi; Daniel E Sturdevant; Stephen F Porcella; Joseph B Domachowske; Jesse D Keicher; Helene F Rosenberg
Journal:  Antiviral Res       Date:  2015-07-02       Impact factor: 5.970

Review 7.  Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.

Authors:  Charles J Russell; Eric A F Simões; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2018-01-11       Impact factor: 2.257

8.  Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection.

Authors:  Stanislaw J Gabryszewski; Ofir Bachar; Kimberly D Dyer; Caroline M Percopo; Kristin E Killoran; Joseph B Domachowske; Helene F Rosenberg
Journal:  J Immunol       Date:  2010-12-17       Impact factor: 5.422

9.  Cell cycle arrest by transforming growth factor beta1 enhances replication of respiratory syncytial virus in lung epithelial cells.

Authors:  John D Gibbs; Douglas M Ornoff; Heather A Igo; Jennifer Y Zeng; Farhad Imani
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

Review 10.  Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.

Authors:  Prasad S Kulkarni; Julia L Hurwitz; Eric A F Simões; Pedro A Piedra
Journal:  Viral Immunol       Date:  2018-01-16       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.